ACT Treats 10th Patient in Embryonic Stem Cell Trials for Macular Degeneration
08:30 EDT 30 Jul 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Advanced Cell Technology, Inc. (“ACT”; OTCBB:
ACTC), a leader in the field of regenerative medicine, today
announced treatment of the final patient in the first patient cohort in
its Phase 1/2 clinical trial for Stargardt’...
Other Sources for this Article
Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT
Corporate Communications
Bill Douglass, 646-450-3615
or
Russo
Partners
Martina Schwarzkopf, Ph.D., 212-845-4292
More From BioPortfolio on "ACT Treats 10th Patient in Embryonic Stem Cell Trials for Macular Degeneration"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
